Evidence map›Paper›PMID 34084332›Full record

ArticleChemical science2020

Engineering base-excised aptamers for highly specific recognition of adenosine.

Yuqing Li, Biwu Liu, Zhicheng Huang, Juewen Liu

Open access · diamondAbstract read
In one paragraph

Article in Chemical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 35 citations in OpenAlex.

  1. Mechanism of Dual-Site Recognition in a Classic DNA Aptamer.Journal of chemical information and modeling · 2024
    Article
  2. Article
  3. Article
  4. Review
  5. Accelerating Post-SELEX Aptamer Engineering Using Exonuclease Digestion.Journal of the American Chemical Society · 2021
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yuqing LiDepartment of Chemistry, Waterloo Institute for Nanotechnology, University of Waterloo Waterloo Ontario N2L 3G1 Canada liujw@uwaterloo.ca.
Biwu LiuDepartment of Chemistry, Waterloo Institute for Nanotechnology, University of Waterloo Waterloo Ontario N2L 3G1 Canada liujw@uwaterloo.ca.
Zhicheng HuangDepartment of Chemistry, Waterloo Institute for Nanotechnology, University of Waterloo Waterloo Ontario N2L 3G1 Canada liujw@uwaterloo.ca.
Juewen LiuDepartment of Chemistry, Waterloo Institute for Nanotechnology, University of Waterloo Waterloo Ontario N2L 3G1 Canada liujw@uwaterloo.ca.ORCID https://orcid.org/0000-0001-5918-9336
University of Waterloo · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The DNA aptamer for adenosine and ATP has been used as a model system for developing analytical biosensors. For practical reasons, it is important to distinguish adenosine from ATP, although this has yet to be achieved despite extensive efforts made on selection of new aptamers. We herein report a strategy of excising an adenine nucleotide from the backbone of a one-site adenosine aptamer, and the adenine-excised aptamer allowed highly specific binding of adenosine. Cognate analytes including AMP, ATP, guanosine, cytidine, uridine, and theophylline all failed to bind to the engineered aptamer according to the SYBR Green I (SGI) fluorescence spectroscopy and isothermal titration calorimetry (ITC) results. Our A-excised aptamer has two binding sites: the original aptamer binding site in the loop and the newly created one due to base excision from the DNA backbone. ITC demonstrated that the A-excised aptamer strand can bind to two adenosine molecules, with a

Identifiers

PMID34084332
PMCPMC8157715
OpenAlexW3004940160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.